Literature DB >> 29410941

Positive and Negative Syndrome Scale (PANSS) Training: Challenges, Solutions, and Future Directions.

Mark G A Opler1,2,3, Christian Yavorsky1,2,3, David G Daniel1,2,3.   

Abstract

Rater training and the maintenance of the consistency of ratings are critical to ensuring reliability of study measures and sensitivity to changes in the course of a clinical trial. The Positive and Negative Syndrome Scale (PANSS) has been widely used in clinical trials of schizophrenia and other disorders and is considered the "gold standard" for assessment of antipsychotic treatment efficacy. The various features associated with training and calibration of this scale are complex, reflecting the intricacy and heterogeneity of the disorders that the PANSS is used to evaluate. In this article, the authors review the methods for ensuring reliability of the PANSS as well as a proposed trajectory for its use in the future. An overview of the current principles, implementation, technologies, and strategies for the best use of the PANSS; tips for how to achieve consistency among raters; and optimal training practices of this instrument are presented.

Entities:  

Keywords:  PANSS; Positive and Negative Syndrome Scale; clinical trials; rater; rater training; technology

Year:  2017        PMID: 29410941      PMCID: PMC5788255     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  16 in total

1.  What does the PANSS mean?

Authors:  Stefan Leucht; John M Kane; Werner Kissling; Johannes Hamann; Eva Etschel; Rolf R Engel
Journal:  Schizophr Res       Date:  2005-06-27       Impact factor: 4.939

2.  The five-factor model of the Positive and Negative Syndrome Scale I: confirmatory factor analysis fails to confirm 25 published five-factor solutions.

Authors:  Mark van der Gaag; Anke Cuijpers; Tonko Hoffman; Mila Remijsen; Ron Hijman; Lieuwe de Haan; Berno van Meijel; Peter N van Harten; Lucia Valmaggia; Marc de Hert; Durk Wiersma
Journal:  Schizophr Res       Date:  2006-05-26       Impact factor: 4.939

3.  PANSS rater training using Internet and videoconference: results from a pilot study.

Authors:  Kenneth A Kobak; Mark G A Opler; Nina Engelhardt
Journal:  Schizophr Res       Date:  2007-03-01       Impact factor: 4.939

4.  Use of remote centralized raters via live 2-way video in a multicenter clinical trial for schizophrenia.

Authors:  Joan Shen; Kenneth A Kobak; Yonggang Zhao; Madeline M Alexander; John M Kane
Journal:  J Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.153

5.  Data Quality Monitoring in Clinical Trials: Has It Been Worth It? An Evaluation and Prediction of the Future by All Stakeholders.

Authors:  David Daniel; Amir Kalali; Mark West; David Walling; Dana Hilt; Nina Engelhardt; Larry Alphs; Antony Loebel; Kim Vanover; Sarah Atkinson; Mark Opler; Gary Sachs; Kari Nations; Chris Brady
Journal:  Innov Clin Neurosci       Date:  2016-02-01

6.  Consistency checks to improve measurement with the Positive and Negative Syndrome Scale (PANSS).

Authors:  Jonathan Rabinowitz; Nina R Schooler; Ariana Anderson; Lindsay Ayearst; David Daniel; Michael Davidson; Anzalee Khan; Bruce Kinon; Francois Menard; Lewis Opler; Mark Opler; Joanne B Severe; David Williamson; Christian Yavorsky; Jun Zhao
Journal:  Schizophr Res       Date:  2017-03-09       Impact factor: 4.939

7.  The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

Authors:  S R Marder; J M Davis; G Chouinard
Journal:  J Clin Psychiatry       Date:  1997-12       Impact factor: 4.384

8.  Explanatory models and concepts of West African Malian patients with psychotic symptoms.

Authors:  F Napo; A Heinz; A Auckenthaler
Journal:  Eur Psychiatry       Date:  2012-06       Impact factor: 5.361

Review 9.  Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?

Authors:  Larry Alphs; Fabrizio Benedetti; W Wolfgang Fleischhacker; John M Kane
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-05       Impact factor: 5.176

10.  The feasibility of using electronic clinical outcome assessments in people with schizophrenia and their informal caregivers.

Authors:  Chloe Tolley; Diana Rofail; Adam Gater; Justine K Lalonde
Journal:  Patient Relat Outcome Meas       Date:  2015-03-26
View more
  11 in total

1.  Testing for Thyroid Peroxidase and Antineuronal Antibodies in Depression and Schizophrenia.

Authors:  Johann Steiner; Winfried Stoecker; Bianca Teegen; Henrik Dobrowolny; Gabriela Meyer-Lotz; Katrin Borucki; Paul C Guest; Hans-Gert Bernstein
Journal:  Methods Mol Biol       Date:  2022

2.  Delaying clozapine: how long is too long?

Authors:  Tom Varghese M; K S Jyothi; K S Shaji; Lekshmi Rita Venugopal
Journal:  Gen Psychiatr       Date:  2020-04-28

3.  Quality of life and its social determinants for patients with schizophrenia and family caregivers in Cambodia.

Authors:  Toshiyuki Marutani; Sotheara Chhim; Akihiro Nishio; Akiko Nosaki; Yasuko Fuse-Nagase
Journal:  PLoS One       Date:  2020-03-04       Impact factor: 3.240

4.  Concordance of Immune-Related Markers in Lymphocytes and Prefrontal Cortex in Schizophrenia.

Authors:  Eleonora Gatta; Vikram Saudagar; Jenny Drnevich; Marc P Forrest; James Auta; Lindsay V Clark; Henry Sershen; Robert C Smith; Dennis R Grayson; John M Davis; Alessandro Guidotti
Journal:  Schizophr Bull Open       Date:  2021-02-06

Review 5.  The Role of Childhood Trauma in Psychosis and Schizophrenia: A Systematic Review.

Authors:  Bithaiah Inyang; Faisal J Gondal; Godwin A Abah; Mahesh Minnal Dhandapani; Manasa Manne; Manish Khanna; Sabitha Challa; Ahmed S Kabeil; Lubna Mohammed
Journal:  Cureus       Date:  2022-01-21

6.  Metabolite Alternations in the Dopamine Circuit Associated with Methamphetamine-Related Psychotic Symptoms: A Proton Magnetic Resonance Spectroscopy Study.

Authors:  Javad Sheikhi Koohsar; Fariborz Faeghi; Raheleh Rafaiee; Mohammad Niroumand Sarvandani; Sadegh Masjoodi; Hamid Kalalian Moghaddam
Journal:  Iran J Psychiatry       Date:  2022-01

7.  Symptom severity is associated with leftward lateralization upon contextual modulation of visual vertical in patients with schizophrenia.

Authors:  Abdul Rima Razzak; Haitham Jahrami; Mariwan Husni; Maryam Ebrahim Ali; Jeff Bagust
Journal:  Front Psychiatry       Date:  2022-07-18       Impact factor: 5.435

8.  Computer Vision-Based Assessment of Motor Functioning in Schizophrenia: Use of Smartphones for Remote Measurement of Schizophrenia Symptomatology.

Authors:  Anzar Abbas; Vijay Yadav; Emma Smith; Elizabeth Ramjas; Sarah B Rutter; Caridad Benavidez; Vidya Koesmahargyo; Li Zhang; Lei Guan; Paul Rosenfield; Mercedes Perez-Rodriguez; Isaac R Galatzer-Levy
Journal:  Digit Biomark       Date:  2021-01-21

9.  Association of rs4680 COMT, rs6280 DRD3, and rs7322347 5HT2A With Clinical Features of Youth-Onset Schizophrenia.

Authors:  Anna Morozova; Yana Zorkina; Konstantin Pavlov; Olga Pavlova; Zinaida Storozheva; Eugene Zubkov; Natalia Zakharova; Olga Karpenko; Alexander Reznik; Vladimir Chekhonin; Georgiy Kostyuk
Journal:  Front Psychiatry       Date:  2019-11-12       Impact factor: 4.157

Review 10.  Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review.

Authors:  William J Cragg; Caroline Hurley; Victoria Yorke-Edwards; Sally P Stenning
Journal:  Clin Trials       Date:  2021-02-20       Impact factor: 2.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.